Almirall, S.A. (LBTSF)
- Previous Close
0.00 - Open
9.75 - Bid 10.40 x 36900
- Ask 11.55 x 36900
- Day's Range
9.75 - 9.75 - 52 Week Range
9.01 - 9.75 - Volume
10 - Avg. Volume
1 - Market Cap (intraday)
2.307B - Beta (5Y Monthly) 0.31
- PE Ratio (TTM)
150.17 - EPS (TTM)
0.06 - Earnings Date May 12, 2025
- Forward Dividend & Yield 0.20 (2.22%)
- Ex-Dividend Date May 17, 2024
- 1y Target Est
--
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, nervous, and respiratory system; dermatologicals; genito urinary system and sex hormones; immunostimulants; metabolism; and systematic hormonal preparations. It has a multi-target partnership with Etherna to research and develop mRNA-based therapies for medical dermatology. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
www.almirall.com2,026
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: LBTSF
View More
Performance Overview: LBTSF
Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is IBEX 35... (^IBEX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LBTSF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LBTSF
View MoreValuation Measures
Market Cap
2.31B
Enterprise Value
2.34B
Trailing P/E
158.76
Forward P/E
13.23
PEG Ratio (5yr expected)
0.76
Price/Sales (ttm)
1.70
Price/Book (mrq)
1.14
Enterprise Value/Revenue
2.10
Enterprise Value/EBITDA
11.90
Financial Highlights
Profitability and Income Statement
Profit Margin
1.02%
Return on Assets (ttm)
1.32%
Return on Equity (ttm)
0.69%
Revenue (ttm)
990.63M
Net Income Avi to Common (ttm)
10.15M
Diluted EPS (ttm)
0.06
Balance Sheet and Cash Flow
Total Cash (mrq)
377.3M
Total Debt/Equity (mrq)
26.41%
Levered Free Cash Flow (ttm)
-32.86M